Medical Condition News

RSS

FDA warns online retailers for illegal tobacco product marketing

The U.S. Food and Drug Administration today announced it issued 11 warning letters last week to online retailers for illegally marketing tobacco products with misleading or unsubstantiated claims or descriptors indicating that they can be used to reduce harm or the risk of tobacco-related disease.

26 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Pulmonx announces new clinical data of Zephyr endobronchial valve in emphysema

Pulmonx Inc. has announced new clinical data from its Chartis multi-center study, presented at the American Thoracic Society's 2011 International Conference.

25 May 2011

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that in the follow-up portion of its Phase 2 clinical trial in patients with diabetic foot ulcers, the percentage of patients treated with the therapeutic dose of DSC127 with complete healing at 24 weeks following trial enrollment was 73% in the intent-to-treat population and 85% in the per-protocol population, a difference of 27 and 33 percentage points, respectively, compared with patients treated with placebo/standard of care.

25 May 2011

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Apollo centre for liver disease and transplantation has completed 100 liver transplantations in less than 4 years with over 90% success rate, creating a milestone in the history of medicine.

25 May 2011

Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors

Pathway Therapeutics, Inc., a company developing novel therapeutics that target the PI3K and mTOR pathways, today announced that the FDA has accepted an IND filing for PWT33597, which allows Pathway to commence Phase 1 clinical testing.

25 May 2011

PPSC, InVivo enter sponsorship deal to support Adaptive Sailing Program for the disabled

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that the Company has entered into a sponsorship agreement with Boston-based Piers Park Sailing Center to support a non-profit sailing initiative for the disabled.

25 May 2011

MKK4 enzyme may prevent arrhythmias linked with cardiac hypertrophy

Scientists have discovered an important enzyme molecule that may prevent fatal cardiac disorders associated with cardiac hypertrophy - the leading cause of sudden cardiac death in young athletes.

25 May 2011

Obesity and diabetes rates continue to rise despite decline in consumption of sweeteners

A comprehensive review of research focusing on the debate between High Fructose Corn Syrup and other sweeteners presented today finds there is no evidence of any significant variation in the way the human body metabolizes HFCS as opposed to standard table sugar, or any difference in impact on risk factors for chronic disease.

25 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

FDA grants approval for CSI to complete enrollment in ORBIT II IDE coronary clinical trial

Cardiovascular Systems, Inc. has received FDA approval to complete enrollment of 429 patients in its ORBIT II Investigational Device Exemption clinical trial for a coronary application for its Diamondback 360 System.

25 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Study examines effects of psychotherapy on cortisol stress hormone

In a study published in the current issue of Psychotherapy and Psychosomatics the effects of psychotherapy on cortisol, the most important stress hormone, are examined.

25 May 2011

Brain areas responsible for motor behavior might represent therapeutic targets for bipolar disorder

A new study by motor control and psychology researchers at Indiana University suggests that postural control problems may be a core feature of bipolar disorder, not just a random symptom, and can provide insights both into areas of the brain affected by the psychiatric disorder and new potential targets for treatment.

25 May 2011

Oral and injected steroids appear to be equally effective for sudden hearing loss

A relatively new treatment for sudden hearing loss that involves injecting steroids into the middle ear appears to work just as well as the current standard of oral steroids, a study by researchers at Johns Hopkins and other institutions suggests.

25 May 2011

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.

25 May 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Novartis announced results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid used to treat gouty arthritis attacks.

25 May 2011

Study to explore whether early depression treatment can reduce risk of heart disease

Jesse Stewart, Ph.D., assistant professor of psychology in the School of Science at Indiana University-Purdue University Indianapolis and an Indiana University Center for Aging Research affiliated scientist, has received a $110,000 grant from the American Heart Association to explore whether treatment of depression before one experiences a heart attack can reduce the likelihood of future heart disease.

25 May 2011

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Proteostasis Therapeutics and Elan Corporation today announced a strategic business relationship to advance Proteostasis' platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis, and a broad array of dementia-related diseases including Alzheimer's.

25 May 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

Medical Condition News

FDA warns online retailers for illegal tobacco product marketing

Lx Therapies, BioCis partner to form Laurantis Pharma

Pulmonx announces new clinical data of Zephyr endobronchial valve in emphysema

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors

PPSC, InVivo enter sponsorship deal to support Adaptive Sailing Program for the disabled

MKK4 enzyme may prevent arrhythmias linked with cardiac hypertrophy

Obesity and diabetes rates continue to rise despite decline in consumption of sweeteners

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

FDA grants approval for CSI to complete enrollment in ORBIT II IDE coronary clinical trial

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Study examines effects of psychotherapy on cortisol stress hormone

Brain areas responsible for motor behavior might represent therapeutic targets for bipolar disorder

Oral and injected steroids appear to be equally effective for sudden hearing loss

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Study to explore whether early depression treatment can reduce risk of heart disease

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News